



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it carries a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef Steuss
		Group Art Unit	1644
		Examiner Name	Francois P Vandervegt
Sheet	3	of	3
		Attorney Docket Number	IMG 101

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	‡
		OGAWA, et al., "Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay", <i>Bone Marrow Transplant</i> , 21(5):525-7 (1998).	
		SHIMAMOTO, et al., "The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia", <i>Blood</i> , 88(8):3173-80 (1995).	
		SILBERSTEIN, et al., "Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 94(15):8132-7 (1997).	
		TJOA, et al., "Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides", <i>Prostate</i> , 32(4):272-8 (1997).	
		TOUROOT, et al., "Chimeric peptides: a new approach to enhancing the immunogenicity of peptides with low MHC class I affinity: application in antiviral vaccination", <i>J. Immunol.</i> , 159(5):2391-8 (1997).	
		VIEL, et al., "Molecular mechanisms possibly affecting WT1 function in human ovarian tumors", <i>Int. J. Cancer</i> , 57(4):515-21 (1994).	
		ZHAI, et al., "Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy", <i>J. Immunol.</i> , 158(2):700-10 (1996).	
		ZON, et al., "The major human erythroid DNA-binding protein (GF-1): primary sequence and localization of the gene to the X chromosome", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 87(2):668-72 (1990).	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

† Unique citation designation number ‡ See attached Kinds of U.S. Patent Documents. § Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. † Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. § Applicant to place a check mark here if English language Translation is attached.

Burdan Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DD NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.